

LTBI prevalence in a Malaysian prison

# 1 High Prevalence of Latent Tuberculosis Infection 2 among Persons Deprived of Liberty in a Malaysian 3 Prison

4  
5 Lu Zhang<sup>1</sup>

6 Rumana Saifi<sup>2</sup>

7 Adeeba Kamarulzaman<sup>2,3</sup>

8 Ahsan Ahmad<sup>2,3</sup>

9 Sangeeth Dhaliwal<sup>2</sup>

10 Saidatul Hanida Mohd Yukhi<sup>2</sup>

11 Nor Akma Ibrahim<sup>2</sup>

12 Hui Moon Koh<sup>3</sup>

13 Frederick L. Altice<sup>1,2,3</sup>

14 Sheela V. Shenoi<sup>1,2,3</sup>

15

## 16 **Affiliations:**

17 <sup>1</sup> Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven,

18 Connecticut, USA

19 <sup>2</sup> Center for Excellence in Research on AIDS, University of Malaya, Kuala Lumpur,

20 Malaysia

21 <sup>3</sup> Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut,

22 USA

23 **Keywords:** Substance use; People with HIV; Hepatitis C, Incarceration

24

## 25 **Corresponding author:**

26 Sheela V Shenoi, MD MPH

27 Yale University School of Medicine

28 135 College Street, Suite 323, New Haven, CT, US 06510

29 Fax: 203.737.4051

30 Email: [sheela.shenoi@yale.edu](mailto:sheela.shenoi@yale.edu)

LTBI prevalence in a Malaysian prison

## 31 **Abstract**

32 Rising tuberculosis incidence and mortality necessitate enhanced attention to  
33 prevention in neglected high-risk venues like correctional facilities. We sought to identify  
34 prevalence and correlates of latent TB infection (LTBI) in Malaysia's largest prison.  
35 From October 2019 to January 2023, people deprived of liberty (PDL) entering Kajang  
36 Prison underwent tuberculin skin testing, sputum examination, chest X-ray, and blood  
37 tests for HIV, HCV, and C-reactive protein (CRP); PDL with active tuberculosis were  
38 excluded. Multivariable logistic regression identified independent correlates of LTBI.  
39 Among 601 men without tuberculosis, median age was 42 (IQR 36-50) years with high  
40 prevalences of HIV (8.8%) and HCV (43.4%). LTBI prevalence was 68.2%  
41 (95%CI[64.4%-71.8%]); independent risk factors included opioid use disorder (OUD,  
42 AOR=1.95; 95%CI[1.25-3.05]), pre-incarceration homelessness (AOR=1.89;  
43 95%CI[1.13-2.50]), and HCV (AOR=1.68; 95%CI[1.13-2.50]). Pre-incarceration  
44 cannabis use (AOR=0.69; 95%CI[0.39-0.96]) was negatively associated with LTBI,  
45 which was also found in people with HIV (AOR=0.10; 95%CI[0.01-0.51]). Among people  
46 without HIV, having OUD (AOR=2.32; 95%CI[1.48-3.68]), HCV (AOR=1.64;  
47 95%CI[1.09-2.48]) and CRP  $\geq 5$ mg/ml (AOR=1.90; 95%CI[1.04-3.65]) were  
48 independently associated with LTBI, while methamphetamine use reduced odds of LTBI  
49 (AOR=0.58; 95%CI[0.33-0.98]). LTBI prevalence in Malaysia's largest prison was high,  
50 highlighting the need for routine screening and implementation of TB preventive therapy  
51 in high-risk settings like prisons.

52

LTBI prevalence in a Malaysian prison

## 53 Introduction

54 Tuberculosis (TB) remains a prominent global health concern despite extensive  
55 efforts to control its spread, especially in resource-limited correctional facilities in low-  
56 and middle-income country (LMIC) where conditions often contribute to the transmission  
57 of the disease.[1] The crowded inmate populations, increased vulnerability due to  
58 complicated comorbidities or medical histories, and continuous interaction increase the  
59 risk of spread.[2] Kajang's prison for men, the largest in Malaysia, exemplifies these  
60 challenges.

61 Latent tuberculosis infection (LTBI) is a precursor for developing active TB  
62 disease, and can be prevented. [3] Coinfection with HIV complicates the LTBI  
63 landscape, making management even more challenging. Therefore, understanding LTBI  
64 prevalence and correlated factors, especially in high-risk populations such as in people  
65 deprived of liberty (PDL), is essential for devising effective preventive and therapeutic  
66 measures.[4]

67 Socio-demographic characteristics, substance use patterns, and other  
68 comorbidities have been identified as key determinants influencing risk for TB  
69 infection,[1,5,6] while substance use, particularly opioid dependence, has been  
70 correlated with an increased risk of acquiring TB.[7] Few studies have examined LTBI in  
71 the incarceration environment where the prevalence of opioid use disorder (OUD) and  
72 HIV are high. We therefore conducted a cross-sectional study of newly entering people  
73 to a prison to estimate the prevalence of LTBI, to discern potential correlates of LTBI  
74 and identify opportunities for better TB control.

75

LTBI prevalence in a Malaysian prison

## 76 **Methods**

77 We conducted a cross-sectional study among PDL in Kajang prison, Malaysia's largest  
78 prison for men, where HIV testing is mandatory and people with HIV (PWH) are  
79 segregated in dedicated housing units. Participants were eligible if within 2 days of  
80 prison entry, age  $\geq 18$  years old, held Malaysian citizenship, their prison sentence was  
81  $>3$  months, and no active TB in the past 2 years. Participants underwent a detailed  
82 interview combined with TB screening and diagnostic testing, including a battery of  
83 tuberculin skin testing (TST), sputum smear for acid-fast bacillus (AFB), sputum testing  
84 using Gene Xpert MTB/RIF, culture for Mycobacterium tuberculosis (MTB) (BACTEC  
85 MGIT 960 System) and chest X-ray (CXR). Those meeting criteria for TB, including  
86 positive findings for TB culture, GeneXpert, and AFB smear were excluded. This study is  
87 reported following the STROBE recommendations (S1 Table) and was approved by the  
88 Institutional Review Boards of Yale University (IRB Number: 2000020053) and the  
89 University of Malaya (IRB Number: 201696-4220), and approved by the Malaysian  
90 Ministry of Health, and Prisons Department. Written informed consent was obtained  
91 from all participants prior to enrollment in the study.

92 Data were collected consecutively between 22<sup>nd</sup> October 2019 and 19<sup>th</sup> January  
93 2023. After written informed consent, eligible participants underwent all TB testing  
94 requirements plus point-of-care HIV, phlebotomy for CRP, hepatitis C virus (HCV) and  
95 hepatitis B virus (HBV) antibody test. All positive HIV tests were confirmed using ELISA  
96 followed by CD4 and viral load testing and referral for antiretroviral therapy. In the  
97 structured survey, sociodemographic variables, substance use history, TB-associated  
98 medical histories including Bacille Calmette-Guerin (BCG) vaccine, TB contact, and

## LTBI prevalence in a Malaysian prison

99 symptom screen were collected. Pre-incarceration opioid dependence was defined  
100 using the Rapid Opioid Dependence Screen (RODS). CXR were performed at the  
101 prison by a mobile service within 1-2 weeks of entry, depending on COVID-19  
102 restrictions, and reviewed by two radiologists; a third reviewer resolved any discordant  
103 results to assess for pulmonary TB. LTBI was confirmed when active TB was ruled out  
104 and the TST size  $\geq 5\text{mm}$  for PWH and  $\geq 10\text{mm}$  for PDL without HIV. The study was  
105 nested within a parent trial evaluating two regimens for TB preventive therapy. The  
106 sample size was influenced by the recruitment for the clinical trial of individuals  
107 determined to have no active TB disease. Initially, the trial enrolled only those with  
108 OUD, but on July 18, 2022, OUD was removed from the eligibility criteria to ensure  
109 generalizability.

110 REDCap was used to record the data and R (version 4.1.0) was used for  
111 statistical analysis. Descriptive statistics including counts and proportions were used to  
112 characterize categorical variables, while means with standard deviation (SD), medians  
113 with interquartile range (IQR), and 95% confidence intervals (CI) were used to  
114 characterize continuous variables. The primary outcome was the diagnosis of LTBI,  
115 operationalized as meeting TST criteria and having active TB excluded. Normality was  
116 checked among all continuous variables by QQ plot. Student's t-test and the Wilcoxon  
117 rank sum test were used to compare parametric and non-parametric continuous  
118 variables, respectively. Chi-square test and Fisher's exact test were used to compare  
119 categorical variables. All predictors with p-value  $\leq 0.10$  from the bivariate analysis were  
120 included into the multivariable model except for 'history of heroin use' due to its  
121 collinearity with diagnosis of pre-incarceration opioid dependence, confirmed using the

LTBI prevalence in a Malaysian prison

122 RODS. Multivariable logistic regression was performed to identify independent  
123 correlates of LTBI using stepwise backward regression. Multicollinearity was assessed  
124 using the variance inflation factor (VIF).

125

## 126 **Results**

127 Among the 935 PDL consecutively entering prison and meeting eligibility criteria, 926  
128 (99.0%) participants enrolled. Among these, 80 were excluded as they had confirmed  
129 pulmonary TB. Another 245 were excluded due to missing data (Fig 1). The final  
130 analysis included 601 male participants with complete data. Table

131 1 provides the characteristics of the sample with the median age as 42 years (IQR 36-  
132 50) and 69.9% identified as Malay. Most participants were Muslim (73.7%), single  
133 (56.2%), and completed secondary school (75.4%). For the prior 6 months before  
134 entering prison, 85.5% of participants were employed full-time and their median monthly  
135 income was 324.3 US dollars, which is approximately 45% below the Malaysia 2022  
136 poverty line of 594.4.[8] All participants had been previously incarcerated (median=8;  
137 IQR 4-14), with a median previous incarceration duration of 5.0 (IQR 2.7-10.0) years.  
138 Among participants, HIV prevalence was high (N=53, 8.8%) as was HCV infection  
139 (N=261, 43.4%). Only 6.3% had been hospitalized in the 6 months prior to entering  
140 prison. In total, 477 (79.4%) participants had OUD and 253 (42.1%) participants  
141 reported injecting drugs before being incarcerated. For participants included after July  
142 18, 2022, the prevalence of OUD was 51.9% (134/258). The prevalence of illegal drug  
143 use was high: heroin ranked highest (509 [84.7%]), followed by methamphetamine (496  
144 [82.5%]), and marijuana (428 [71.2%]).

LTBI prevalence in a Malaysian prison

145 **Fig 1. Patient flow chart.**

**Table 1. Comparison of full baseline characteristics, stratified by LTBI status (N=601)**

Predictors (Mean [SD] / N [%])	LTBI-negative (N=191)	LTBI-positive (N=410)	Total (N=601)	P value <sup>1</sup>
Age	41.4 (10.0)	43.34 (9.6)	42.7 (9.8)	0.025*
Race				0.564
Malay	136 (71.2%)	284 (69.3%)	420 (69.9%)	
Chinese	18 (9.4%)	38 (9.3%)	56 (9.3%)	
Indian	30 (15.7%)	79 (19.3%)	109 (18.1%)	
Other	7 (3.7%)	9 (2.2%)	16 (2.7%)	
Religion				0.379
Islam	147 (77.0%)	296 (72.2%)	443 (73.7%)	
Christianity	12 (6.3%)	20 (4.9%)	32 (5.3%)	
Buddhism	11 (5.8%)	27 (6.6%)	38 (6.3%)	
Hinduism	19 (9.9%)	64 (15.6%)	83 (13.8%)	
Other	2 (1.0%)	3 (0.7%)	5 (0.8%)	
Marital status				0.391
Single	102 (53.4%)	236 (57.6%)	338 (56.2%)	
Married	41 (21.5%)	87 (21.2%)	128 (21.3%)	
Separated	10 (5.2%)	27 (6.6%)	37 (6.2%)	
Widowed	38 (19.9%)	60 (14.6%)	98 (16.3%)	
Education level				0.351
Primary school and below	35 (18.3%)	95 (23.2%)	130 (21.6%)	
Secondary school	149 (78.0%)	304 (74.1%)	453 (75.4%)	
Above Secondary school	7 (3.7%)	11 (2.7%)	18 (3.0%)	
Employed prior to incarceration	171 (89.5%)	343 (83.7%)	514 (85.5%)	0.057
Income prior to incarceration (USD/month)	410.7(512.3)	450.9 (1690.5)	438.2 (1425.3)	0.748
Hospitalization in the past 6 months	12 (6.3%)	26 (6.3%)	38 (6.3%)	0.978
Number of prior incarcerations	9.0 (7.3)	10.5 (7.6)	10.0 (7.6)	0.030*
IVDU	60 (31.4%)	193 (47.1%)	253 (42.1%)	< 0.001***
Opioid dependence	130 (68.1%)	347 (84.6%)	477 (79.4%)	< 0.001***
BCG vaccine	183 (95.8%)	399 (97.3%)	582 (96.8%)	0.326
Homelessness	17 (8.9%)	76 (18.5%)	93 (15.5%)	0.002**
TB contact	30 (15.7%)	93 (22.7%)	123 (20.5%)	0.048*
Marijuana	152 (79.6%)	276 (67.3%)	428 (71.2%)	0.002**
Heroin	149 (78.0%)	360 (87.8%)	509 (84.7%)	0.002**
Cocaine	21 (11.0%)	50 (12.2%)	71 (11.8%)	0.671
Methamphetamine	168 (88.0%)	328 (80.0%)	496 (82.5%)	0.017*
MDMA	26 (13.6%)	45 (11.0%)	71 (11.8%)	0.351
GHB	4 (2.1%)	7 (1.7%)	11 (1.8%)	0.742
Ketamine	48 (25.1%)	84 (20.5%)	132 (22.0%)	0.200
Inhalants	23 (12.0%)	61 (14.9%)	84 (14.0%)	0.350
Kratom leaves	70 (36.6%)	134 (32.7%)	204 (33.9%)	0.339
BMI	22.1 (3.2)	22.1 (2.9)	22.1 (3.0)	0.730
HIV	15 (7.9%)	38 (9.3%)	53 (8.8%)	0.569
Currently taking ART	8 (4.2%)	28 (6.8%)	36 (6.0%)	0.184
HIV Viral load ≥200 copies/mL	11 (5.8%)	20 (4.9%)	31 (5.2%)	0.649

## LTBI prevalence in a Malaysian prison

HCV	58 (30.4%)	203 (49.5%)	261 (43.4%)	< 0.001***
HBV	1 (0.5%)	6 (1.5%)	7 (1.2%)	0.317
CRP ≥5mg/L	18 (9.4%)	58 (14.1%)	76 (12.6%)	0.105
CXR concerning for TB	36 (18.8%)	121 (29.5%)	157 (26.1%)	0.006**

Abbreviations: LTBI, latent tuberculosis infection; SD, standard deviation; IVDU, intravenous drug user; BCG, bacille Calmette-Guerin; TB, tuberculosis; MDMA, 3,4-Methylenedioxyamphetamine; GHB, Gamma-hydroxybutyrate; BMI, Body mass index; HIV, human immunodeficiency virus; ART, antiretroviral therapy; HCV, hepatitis C virus; HBV, hepatitis B virus; CRP, C-reactive protein; CXR, chest X-ray.

1: \*P<0.05; \*\*P<0.01; \*\*\*P<0.001

146

147 The prevalence of LTBI was 68.2% (95%CI: 64.4%-71.8%) and higher among  
 148 PWH (77.4%; 95%CI: 67.2%-87.7%).The LTBI prevalence among PDL without HIV was  
 149 67.9% (95%CI: 64.0%-71.8%). The vast majority (96.8%) of participants reported  
 150 receiving the BCG vaccine, 123 (20.5%) reported contact with someone with TB, and  
 151 15.5% reported a history of homelessness (Table 1).

152 On multivariable analysis, independent risk factors for LTBI among all PDL  
 153 (Table 2) included OUD history (Adjusted odds ratio [AOR] = 1.95 [95%CI: 1.25-3.05],  
 154 p=0.003), history of homelessness (AOR = 1.89[95%CI: 1.09-3.45], p=0.03) and having  
 155 hepatitis C (AOR = 1.68 [95%CI: 1.13-2.50], p=0.01). Marijuana use was the only  
 156 independent factor associated with less risk of LTBI (AOR = 0.69 [95%CI: 0.39-0.96],  
 157 p=0.035).

**Table 2. Correlates of LTBI among new entrants to prison (N=601)**

Variables <sup>1</sup>	Univariable analysis		Multivariable analysis <sup>2</sup>	
	OR (95% CI)	P value	AOR (95% CI)	P value <sup>3</sup>
Age	1.021 (1.003-1.039)	0.026*	--	--
Pre-incarceration:				
Employed prior to incarceration	0.599 (0.344-1.002)	0.059	--	--
Number of prior incarcerations	1.027 (1.003-1.053)	0.031*	--	--
Drug injection	1.942 (1.357-2.801)	<0.001***	--	--
Opioid dependence	2.584	<0.001***	1.952	0.003**



### LTBI prevalence in a Malaysian prison

	(1.722-3.882)		(1.252-3.047)	
Homelessness	2.329	0.003**	1.891	0.030*
	(1.365-4.186)		(1.087-3.452)	
TB contact	1.574	0.050	--	--
	(1.011-2.510)			
Marijuana	0.528	0.002**	0.619	0.035*
	(0.348-0.789)		(0.393-0.960)	
Methamphetamine	0.548	0.018*	0.628	0.098
	(0.326-0.888)		(0.356-1.077)	
Heroin	2.030	0.002**	--	--
	(1.287-3.189)			
After-incarceration:				
HCV	2.249	<0.001***	1.677	0.011*
	(1.569-3.253)		(1.130-2.501)	
CXR concerning for TB	1.803	0.006**	1.440	0.104
	(1.194-2.773)		(0.934-2.255)	

Abbreviations: LTBI, latent tuberculosis infection; OR, odds ratio; AOR: adjusted odds ratio; CI, confidence interval; IVDU, intravenous drug user; HCV, hepatitis C; CRP: C-reactive protein; CXR, chest X-ray; TB, tuberculosis.

1: Only variables with P values <0.10 in univariable analysis are listed here.

2: Stepwise backward regression was applied in multivariable model. No multicollinearity detected since all three adjusted models had VIFs less than 1.2.

3: \*P<0.05; \*\*P<0.01; \*\*\*P<0.001

158

159 For PWH (Table 3), comorbid HCV increased the odds of LTBI (AOR = 3.86  
 160 [95%CI 0.88-18.6], p=0.078) while the history of marijuana use was associated with  
 161 lower odds for LTBI (AOR = 0.10 [95%CI: 0.01-0.51], p=0.01). For PDL without HIV  
 162 (Table 4), participants who had OUD history (AOR = 2.32 [95%CI: 1.48-3.68], p<0.001),  
 163 having hepatitis C (AOR = 1.64 [95%CI: 1.09-2.48], p=0.018) and CRP ≥5mg/ml (AOR  
 164 = 1.90 [95%CI: 1.04-3.65], p=0.044) are independent risk factors for LTBI, while the  
 165 history of methamphetamine use was associated with lower odds of LTBI (AOR = 0.58  
 166 [95%CI: 0.33-0.98], p=0.048). All PWH had a history of homelessness or hospitalization  
 167 in the past 6 months, which indicates that these two factors may be potential LTBI risk  
 168 factors among PWH, which need more data to explore.

**Table 3. Correlates of LTBI among people with HIV (N=53)**

Variables <sup>1</sup>	Univariable analysis		Multivariable analysis <sup>2</sup>	
	OR (95% CI)	P value	AOR (95% CI)	P value <sup>3</sup>
Pre-incarceration:				
Income prior to incarceration	0.999	0.037*	--	--

## LTBI prevalence in a Malaysian prison

	(0.998-1.000)			
Drug injection	7.778 (1.717-43.023)	0.010*	--	--
Marijuana	0.138 (0.020-0.590)	0.017*	0.104 (0.013-0.510)	0.011*
Ketamine	0.227 (0.053-0.913)	0.038*	--	--
After-incarceration:				
HCV	6.444 (1.819-25.761)	0.005**	3.855 (0.877-18.627)	0.078
CXR concerning for TB	7.280 (1.242-139.270)	0.069	7.392 (0.963-155.432)	0.091

Abbreviations: LTBI, latent tuberculosis infection; HIV, human immunodeficiency virus; OR, odds ratio; AOR: adjusted odds ratio; CI, confidence interval; IVU, intravenous drug user; HCV, hepatitis C; CRP: C-reactive protein; CXR, chest X-ray; TB, tuberculosis.

1: Only variables with P values <0.10 in univariable analysis are listed here.

2: Stepwise backward regression was applied in multivariable model. No multicollinearity detected since all three adjusted models had VIFs less than 1.2.

3: \*P<0.05; \*\*P<0.01; \*\*\*P<0.001

169

**Table 4. Correlates of LTBI among people without HIV (N=548)**

Variables <sup>1</sup>	Univariable analysis		Multivariable analysis <sup>2</sup>	
	OR (95% CI)	P value	AOR (95% CI)	P value <sup>3</sup>
Age	1.019 (1.001-1.038)	0.041*	--	--
Pre-incarceration:				
Number of prior incarcerations	1.025 (1.000-1.052)	0.054	--	--
Drug injection	1.810 (1.237-2.675)	0.003**	--	--
Opioid dependence	2.521 (1.665-3.823)	<0.001***	2.327 (1.479-3.677)	<0.001***
Homelessness	1.871 (1.081-3.399)	0.031*	--	--
Marijuana	0.602 (0.390-0.914)	0.019*	--	--
Methamphetamine	0.585 (0.343-0.964)	0.041*	0.581 (0.332-0.982)	0.048*
Heroin	2.002 (1.259-3.173)	0.003**	--	--
After-incarceration:				
HCV	2.039 (1.399-3.001)	<0.001***	1.639 (1.090-2.480)	0.018*
CRP ≥ 5 mg/L	1.698 (0.963-3.151)	0.078	1.901 (1.040-3.645)	0.044*
CXR concerning for TB	1.648 (1.078-2.566)	0.024*	--	--

Abbreviations: LTBI, latent tuberculosis infection; HIV, human immunodeficiency virus; OR, odds ratio; AOR: adjusted odds ratio; CI, confidence interval; HCV, hepatitis C; CRP, C-reactive protein; CXR, chest X-ray; TB, tuberculosis.

1: Only variables with P values <0.10 in univariable analysis are listed here.

## LTBI prevalence in a Malaysian prison

---

2: Stepwise backward regression was applied in multivariable model. No multicollinearity detected since all three adjusted models had VIFs less than 1.2.

3: \*P<0.05; \*\*P<0.01; \*\*\*P<0.001

170

171

## 172 Discussion

173 To our knowledge, this is the first systematic assessment of LTBI prevalence using  
174 microbiological assessment to gauge the absence of active TB among PDL in Malaysia,  
175 a upper middle-income country with a high prevalence of HIV, TB, HCV, and  
176 OUD.[9,10] In this large cross-sectional study assessing LTBI among PDL, we found a  
177 high LTBI prevalence at 68.2%. Among PDL overall, OUD, a history of homelessness,  
178 and hepatitis C were associated with higher odds of LTBI. No specific LTBI risk factors  
179 were identified in the subset of PDL with HIV. This high LTBI prevalence highlights the  
180 need for targeted screening and preventive therapy in correctional facilities.

181 Malaysia is a medium TB burden country with a stable LTBI prevalence rate from  
182 28.2% in 1990 to 25.5% in 2019 among the general population,[11] much lower than  
183 among PDL from our study. Prisons are known to be hotspots for TB transmission given  
184 the vulnerabilities of PDL and the structural characteristics of prisons that facilitate  
185 transmission.[12,13] Data on the prevalence of LTBI in prisons is sparse. A study in  
186 western Ethiopia demonstrated a LTBI prevalence of 51.2%; a study in Columbia  
187 showed 46.4% prevalence among PDL with less than 3 months of incarceration but  
188 70.5% prevalence in cases with more than 1 year of incarceration.[14,15] These values  
189 were higher than recent prison studies in high-income countries: 7.1% in the United  
190 Kingdom,[16] and 13.4% in Texas, the United States.[17] While the LTBI prevalence of  
191 another prison in Malaysia 10 years ago was reported as 87.6%, higher than our study

## LTBI prevalence in a Malaysian prison

192 result, though this study was based on symptom screen and TST only.[2] Rising  
193 prevalence of HIV, HCV, and PWUD are major contributors to these epidemics among  
194 incarcerated populations.[5,18] As increasing evidence identifies prisons as TB  
195 transmission hotspots and sources of active tuberculosis for surrounding  
196 communities,[19] there is increased interest in promoting TB preventive therapy in  
197 prison settings.[20] The WHO consolidated guidelines on TB prevention have  
198 recommended all patients living with HIV without active TB should receive TB  
199 preventive therapy, and in 2020, the WHO expanded guidance to recommend that  
200 people in prison receive systematic LTBI testing and treatment as well.[21] As prisons  
201 concentrate high-risk populations, PDL should be screened systematically at their  
202 admissions, with subsequent TB preventive therapy.[6,20] Further evidence about  
203 implementation models of TB preventive therapy in prison settings, and the impact of  
204 TB preventive therapy among PDL are needed.

205 Our study showed OUD and hepatitis C infection were both risk factors among  
206 general PDL and prisoners living without HIV, and OUD had higher ORs than HCV  
207 infection in both subsets. HCV is likely a marker of substance use, particularly  
208 intravenous drug users (IVDU), though IVDU was not significant on multivariable  
209 analysis among all three subsets in our study. This relationship has also been reported  
210 in other developed countries with a high prevalence of IVDU.[22,23] PWUD has been  
211 proved as a risk group of LTBI by many studies and WHO,[7,16,21,24,25] but there has  
212 been debate on whether this is due to behavior, i.e. close contact with someone with  
213 active TB disease or because of substance use-related immunologic susceptibility.[23]  
214 This study showed that neither intravenous access nor inhalants showed an

## LTBI prevalence in a Malaysian prison

215 independent association with LTBI under the adjusted regression model, and opioid use  
216 is the only drug-related risk factor. The lack of specific risk correlates among PDL with  
217 HIV may be due to a limited sample size. In previous studies, elevated CRP had shown  
218 value as a screening tool for active TB among PWH.[26] As for LTBI, CRP was not  
219 significantly correlated among PWH, but elevated CRP was an independent risk factor  
220 among PDL without HIV based on our analysis.

221 We collected substance use details among all PWUD and surprisingly found  
222 marijuana was significantly associated with less risk of LTBI among general PDL and  
223 among PDL with HIV, while methamphetamine showed lower odds of LTBI among PDL  
224 without HIV. Multiple drug use could lead to a lower frequency of opioid use even if the  
225 participant was identified with OUD. A systematic review found that marijuana use may  
226 be a risk factor for LTBI, though this was based on only 2 cross-sectional studies. It is  
227 plausible that non-opioid drug use is less risky for LTBI since there may be less  
228 individual close contact than with OUD.[27] Clinicians assessing patients for  
229 tuberculosis frequently lump together all substance use; further research could allow for  
230 further discrimination of risk.

231 We explored LTBI prevalence and respective correlates based on HIV status in  
232 correctional settings, which emphasizes the importance of screening and care pathways  
233 in different populations. It also highlights the importance of screening upon prison entry  
234 as early evaluation can identify high-risk groups for active TB and support timely active  
235 TB and LTBI treatment initiation and completion. Our findings identify substance use as  
236 a significant risk factor for LTBI highlighting the importance of substance use screening  
237 and treatment integration into TB care in prison settings. Additionally, the study's use of

## LTBI prevalence in a Malaysian prison

238 comprehensive diagnostic methods (TB culture, Xpert, AFB smear) ensured a robust  
239 exclusion of active TB.

240 We recognize several limitations. In the parent study, investigators were denied  
241 access to the women's prison, thus the findings identified in this evaluation may not be  
242 generalizable to women who are incarcerated. Next, the sample has a high prevalence  
243 of OUD since the parent study initially included OUD as an eligibility criterion, and thus  
244 the findings may not be generalizable to prison settings where OUD is less prevalent,  
245 though this scenario is uncommon based on available global data.[2,5,14,28]  
246 Furthermore, the study relied on TST, which is less sensitive and specific than  
247 interferon-gamma release assays (IGRA).[29] The inclusion of adults lowers the false-  
248 positive risk among BCG-vaccinated population since the effects of BCG wane within 8–  
249 10 years[2]. Lastly, the proportion of PWH was small, limiting analyses for this  
250 subgroup.

251 In conclusion, the prevalence of LTBI in Malaysian prisoners was high, nearly  
252 three times of the general population, which highlights the need for screening and the  
253 implementation of TB preventive therapy to reduce risk amongst PDL, staff, and to the  
254 general population. Among newly admitted PDL, opioid use history and HCV are the  
255 main risk factors for LTBI, especially for PDL living without HIV. LTBI is also associated  
256 with the history of homelessness for general PDL and elevated CRP for PDL living  
257 without HIV. Substance use including marijuana and methamphetamine are associated  
258 with lower odds of LTBI. Hence, screening algorithms based on HIV status, HCV status,  
259 drug use history, and homelessness may be useful in stratifying risk upon prison entry.

LTBI prevalence in a Malaysian prison

260 Further evidence-based approaches are also needed in the implementation of TB  
261 preventive therapy among PDL.

262

## 263 **Acknowledgment**

264 We are grateful to Kajang Prison, Prisons Department, and the Malaysian Ministry of  
265 Health. We thank our staff and colleagues at University of Malaya Centre of Excellence  
266 for Research in AIDS (CERIA) and Yale University. Additionally, we convey our sincere  
267 thanks to the persons deprived of liberty who consented to partake in the survey. We  
268 have no conflicts of interest to declare.

269

## LTBI prevalence in a Malaysian prison

### 270 **Reference:**

- 271 1. Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, et al. The  
272 perfect storm: incarceration and the high-risk environment perpetuating  
273 transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and  
274 Central Asia. *The Lancet*. 2016 Sep;388(10050):1228–48.
- 275 2. Margolis B, Al-Darraj HAA, Wickersham JA, Kamarulzaman A, Altice FL.  
276 Prevalence of tuberculosis symptoms and latent tuberculous infection among  
277 prisoners in northeastern Malaysia. *Int J Tuberc Lung Dis*. 2013 Dec;17(12):1538–  
278 44.
- 279 3. Latent tuberculosis infection: updated and consolidated guidelines for programmatic  
280 management [Internet]. Geneva: World Health Organization; 2018 [cited 2023 Oct  
281 4]. (WHO Guidelines Approved by the Guidelines Review Committee). Available  
282 from: <http://www.ncbi.nlm.nih.gov/books/NBK531235/>
- 283 4. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al.  
284 Management of latent Mycobacterium tuberculosis infection: WHO guidelines for  
285 low tuberculosis burden countries. *European Respiratory Journal*. 2015 Dec  
286 1;46(6):1563–76.
- 287 5. Culbert GJ, Pillai V, Bick J, Al-Darraj HA, Wickersham JA, Wegman MP, et al.  
288 Confronting the HIV, Tuberculosis, Addiction, and Incarceration Syndemic in  
289 Southeast Asia: Lessons Learned from Malaysia. *J Neuroimmune Pharmacol*.  
290 2016 Sep;11(3):446–55.
- 291 6. Charalambous S, Velen K, Rueda Z, Croda J, Herce ME, Sheno SV, et al. Scaling  
292 up evidence-based approaches to tuberculosis screening in prisons. *The Lancet*  
293 *Public Health*. 2023 Apr;8(4):e305–10.
- 294 7. Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and Drug Use: Review and  
295 Update. *Clin Infect Dis*. 2009 Jan 1;48(1):10.1086/594126.
- 296 8. Malaysia D of S. Household Income and Expenditure: States | OpenDOSM  
297 [Internet]. [cited 2024 Sep 2]. Available from: <https://open.dosm.gov.my>
- 298 9. Wickersham JA, Zahari MM, Azar MM, Kamarulzaman A, Altice FL. Methadone  
299 dose at the time of release from prison significantly influences retention in  
300 treatment: Implications from a pilot study of HIV-infected prisoners transitioning to  
301 the community in Malaysia. *Drug and Alcohol Dependence*. 2013 Sep;132(1–  
302 2):378–82.
- 303 10. Al-Darraj HAA, Altice FL, Kamarulzaman A. Undiagnosed pulmonary tuberculosis  
304 among prisoners in Malaysia: an overlooked risk for tuberculosis in the community.  
305 *Trop Med Int Health*. 2016 Aug;21(8):1049–58.



## LTBI prevalence in a Malaysian prison

- 306 11. Ding C, Hu M, Guo W, Hu W, Li X, Wang S, et al. Prevalence trends of latent  
307 tuberculosis infection at the global, regional, and country levels from 1990–2019.  
308 *International Journal of Infectious Diseases*. 2022 Sep 1;122:46–62.
- 309 12. Martinez L, Warren JL, Harries AD, Croda J, Espinal MA, Olarte RAL, et al. Global,  
310 regional, and national estimates of tuberculosis incidence and case detection  
311 among incarcerated individuals from 2000 to 2019: a systematic analysis. *The*  
312 *Lancet Public Health*. 2023 Jul 1;8(7):e511–9.
- 313 13. Cords O, Martinez L, Warren JL, O’Marr JM, Walter KS, Cohen T, et al. Incidence  
314 and prevalence of tuberculosis in incarcerated populations: a systematic review  
315 and meta-analysis. *The Lancet Public Health*. 2021 May;6(5):e300–8.
- 316 14. Chekesa B, Gumi B, Chanyalew M, Zewude A, Ameni G. Prevalence of latent  
317 tuberculosis infection and associated risk factors in prison in East Wollega Zone of  
318 western Ethiopia. Ehtesham HS, editor. *PLoS ONE*. 2020 May 19;15(5):e0233314.
- 319 15. Herrera M, Keynan Y, López L, Marín D, Arroyave L, Arbeláez MP, et al. Incidence  
320 and Risk Factors Associated with Latent Tuberculosis Infection and Pulmonary  
321 Tuberculosis among People Deprived of Liberty in Colombian Prisons. *Am J Trop*  
322 *Med Hyg*. 2022 Jan;106(1):66–74.
- 323 16. Gray BJ, Perrett SE, Gudgeon B, Shankar AG. Investigating the prevalence of  
324 latent Tuberculosis infection in a UK remand prison. *J Public Health (Oxf)*. 2020  
325 Feb 28;42(1):e12–7.
- 326 17. Nijhawan AE, Iroh PA, Brown LS, Winetsky D, Porsa E. Cost analysis of tuberculin  
327 skin test and the QuantiFERON-TB Gold In-tube test for tuberculosis screening in a  
328 correctional setting in Dallas, Texas, USA. *BMC Infect Dis*. 2016 Oct 12;16(1):564.
- 329 18. Dolan K, Moazen B, Noori A, Rahimzadeh S, Farzadfar F, Hariga F. People who  
330 inject drugs in prison: HIV prevalence, transmission and prevention. *Int J Drug*  
331 *Policy*. 2015 Feb;26 Suppl 1:S12-15.
- 332 19. Walter KS, Dos Santos PCP, Gonçalves TO, da Silva BO, da Silva Santos A, de  
333 Cássia Leite A, et al. The role of prisons in disseminating tuberculosis in Brazil: A  
334 genomic epidemiology study. *Lancet Reg Health Am*. 2022 May;9:100186.
- 335 20. Narayan A, Salindri AD, Keshavjee S, Muyoyeta M, Velen K, Rueda ZV, et al.  
336 Prioritizing persons deprived of liberty in global guidelines for tuberculosis  
337 preventive treatment. *PLoS Med*. 2023 Oct 3;20(10):e1004288.
- 338 21. WHO operational handbook on tuberculosis (Module 1 – Prevention): Tuberculosis  
339 preventive treatment . Geneva, World Health Organization. 2020.
- 340 22. López de Goicoechea-Saiz M, Sternberg F, Portilla-Sogorb J. Prevalence and  
341 associated risk factors of latent tuberculosis infection in a Spanish prison. *Rev Esp*  
342 *Sanid Penit*. 2018;20(1):4–10.


## LTBI prevalence in a Malaysian prison

- 343 23. Weant TE, Turner AN, Murphy-Weiss M, Murray DM, Wang SH. Can Social History  
344 Variables Predict Prison Inmates' Risk for Latent Tuberculosis Infection? *Tuberc*  
345 *Res Treat.* 2012;2012:132406.
- 346 24. Arroyave L, Keynan Y, Sanchez D, López L, Marin D, Posada M, et al. Guards in  
347 Prisons: A Risk Group for Latent Tuberculosis Infection. *J Immigr Minor Health.*  
348 2019 Jun;21(3):578–85.
- 349 25. de Navarro PD, de Almeida IN, Kritski AL, Ceccato M das G, Maciel MMD,  
350 Carvalho W da S, et al. Prevalence of latent Mycobacterium tuberculosis infection  
351 in prisoners. *J Bras Pneumol.* 2016;42(5):348–55.
- 352 26. Yoon C, Semitala FC, Atuhumuza E, Katende J, Mwebe S, Asege L, et al. Point-of-  
353 care C-reactive protein-based tuberculosis screening for people living with HIV: a  
354 diagnostic accuracy study. *Lancet Infect Dis.* 2017 Dec;17(12):1285–92.
- 355 27. French CE, Coope CM, McGuinness LA, Beck CR, Newitt S, Ahyow L, et al.  
356 Cannabis use and the risk of tuberculosis: a systematic review. *BMC Public Health.*  
357 2019 Jul 27;19:1006.
- 358 28. Izenberg JM, Bachireddy C, Wickersham JA, Soule M, Kiriazova T, Dvoriak S, et  
359 al. Within-prison drug injection among HIV-infected Ukrainian prisoners: prevalence  
360 and correlates of an extremely high-risk behaviour. *Int J Drug Policy.* 2014  
361 Sep;25(5):845–52.
- 362 29. Takasaki J, Manabe T, Morino E, Muto Y, Hashimoto M, Iikura M, et al. Sensitivity  
363 and specificity of QuantiFERON-TB Gold Plus compared with QuantiFERON-TB  
364 Gold In-Tube and T-SPOT.TB on active tuberculosis in Japan. *J Infect Chemother.*  
365 2018 Mar;24(3):188–92.
- 366
- 367

LTBI prevalence in a Malaysian prison

## 368 **Supporting information**

### 369 **S1 Table. STROBE Checklist of cross-sectional studies**



Abbreviations: PDL, persons deprived of liberty; TB, tuberculosis; RODS, Rapid Opioid Dependence Screen; AFB, Acid-Fast Bacillus ; TST, tuberculin skin testing ; CRP, C-reactive protein ; CXR, chest X-ray; SES: socioeconomic status.